Pharmaceutical Industry

U.S. Supreme Court denies Maryland bid to revive law aimed at preventing 'monstrous' generic drug price increases

U.S. Supreme Court denies Maryland bid to revive law aimed at preventing 'monstrous' generic drug price increases

The U.S. Supreme Court has rejected Maryland’s bid to restore a law that state Attorney General Brian Frosh said was needed to protect residents from “monstrous price increases” by generic drug makers.

The high court declined Tuesday to review a federal appeals court's decision striking down the law, which Frosh and health care advocates championed as a groundbreaking attempt to rein in skyrocketing prescription costs.

The court’s decision was a setback to new efforts by states to keep down the cost of medicines. The law briefly went into effect, starting in 2017, before the 4th U.S. Circuit Court of Appeals put it on hold with

32°